Sally Susman waves goodbye to Pfizer Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 11 July, 2025

The biotech companies everyone will be talking about in 2025 get revealed live in Boston this September. Endpoints 11 isn’t just any list — it’s where industry insiders gather to see which bold bets might pay off. Find out who wins in real time at the State Room — reserve your spot now and save with the Early Bird rate.

presented by Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

spotlight Bioregnum Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

news FDA hands Capricor a CRL for its Duchenne muscular dystrophy cell therapy  Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities Peer Review Sally Susman waves goodbye to Pfizer; Xaira's new president and COO

Jul 22 2:00pm ET New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform sponsored by Natera Jul 24 12:00pm ET Predict tumor response and identify more patients for therapy with epigenomic biomarkers sponsored by Guardant

Post-Hoc Live is now available to stream. Catch full episodes on YouTube or listen on Spotify and Apple Podcasts. Be sure to subscribe so you don’t miss what’s next.

endpoints pharma Moderna wins FDA approval for Covid shot in at-risk kids; Makary, Prasad defend vaccine framework Varda raises $187M to advance drug manufacturing in space Jazz taps current COO Renée Galá to replace CEO and co-founder Bruce Cozadd

in case you missed it 1. Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future 2. Watch Post-Hoc Live: Is China a threat or investment opportunity for the US? 3. Swiss and German radiopharma biotech Nuclidium collects $99M Series B 4. Soleno's first wave of rare disease drug sales beats expectations 5. AbbVie inks $700M deal with IGI for multiple myeloma trispecific antibody 6. Ultragenyx, Mereo’s bone disease drug misses second interim analysis, stocks plummet 7. Kidney health biotech emerges with $54M to follow in Vertex’s footsteps 8. Aqtual raises $31M to guide rheumatoid arthritis treatments 9.